Cellectis

@cellectis

Cellectis is gene editing the first of its kind, off-the-shelf UCART immunotherapies to fight blood cancers. Community Guidelines:

Paris, New York & Raleigh
Vrijeme pridruživanja: listopad 2009.

Tweetovi

Blokirali ste korisnika/cu @cellectis

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @cellectis

  1. 4. velj

    Today is and our team is sharing their pledges across our three Cellectis locations. What is your pledge for 2020?

    Poništi
  2. 3. velj

    Tomorrow is . Cellectis is participating and you can, too! Learn from about the many ways to show your support here:

    Poništi
  3. proslijedio/la je Tweet
    31. sij

    Reprogrammation des , course à la maîtrise de l’ : « une nouvelle ère s’ouvre » grâce aux d’édition du génome. Intervention d’André Choulika, directeur de cc

    Poništi
  4. proslijedio/la je Tweet

    CEO André Choulika on what he is looking forward to in 2020. See all current ETF holdings: 

    Poništi
  5. 22. sij

    January is ! Blood is needed as frequently as every 2 seconds in the US for cancer and other reasons, and with cold & flu season in full effect, this month reminds us to donate blood when we can to help those who need it most.

    Poništi
  6. 15. sij

    The AMELI-01 trial evaluates our UCART123 product candidate which has a new construct & optimized production process under a second IND approved by the FDA. Today, we announced the first patient living with AML in this new trial has been dosed. Learn more:

    Poništi
  7. 12. sij

    Today we announced a research collaboration and exclusive worldwide license agreement with Iovance Biotherapeutics. Read more here:

    Poništi
  8. 6. sij

    What are the upcoming promises and current challenges of allogeneic CAR-T cell therapy for cancer? Find out more in a recent review by Cellectis and leading experts published in

    Poništi
  9. 23. pro 2019.

    On behalf of the entire Cellectis team, we wish you and your families a safe and happy holiday season!

    Poništi
  10. 20. pro 2019.

    We’re committed to a cure, and are looking for more dedicated people to join our team! Check out our new Careers page on our website for opportunities in Paris, New York and Raleigh:

    Poništi
  11. 10. pro 2019.

    We are currently building two state-of-the-art manufacturing facilities to become fully equipped to manufacture our product candidates in-house. Learn more:

    Poništi
  12. 2. pro 2019.

    We announced today the dosing of the first patient in our UCART22 Phase 1 clinical study, BALLI-01, for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Read more:

    Poništi
  13. 28. stu 2019.

    Wishing everyone a happy and safe holiday weekend!

    Poništi
  14. 20. stu 2019.

    Today we announced the decision to maintain our patent for a method of gene editing using CRISPR-Cas9 technology. Read more:

    Poništi
  15. 15. stu 2019.

    Interested in joining Cellectis? We’re hiring in our Paris, New York and Raleigh locations. Check out our open positions:

    Poništi
  16. proslijedio/la je Tweet

    . Details Proof-of-Concept for “Smart” CAR T-Cells:

    Poništi
  17. 13. stu 2019.

    We are pleased to announce our article highlighting a proof-of-concept for creating smart CAR T-cells that can sense and react to their environment was published today in . Learn more about this publication:

    Poništi
  18. 7. stu 2019.

    Don’t forget to tune into our Q3 and first nine months 2019 financial results conference call today! Details on how to join:

    Poništi
  19. 6. stu 2019.

    Today we reported our financial results for the third quarter and first nine months of 2019. Read more here:

    Poništi
  20. 31. lis 2019.

    We will be announcing our Q3 & first nine months 2019 financial results on Wednesday, November 6, followed by a conference call on Thursday, November 7 at 8:00 AM EST / 2:00 PM CET. Learn more here:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·